Insight into the role of TRAIL in liver diseases - 06/01/19
pages | 5 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | TRAIL is primarily involved in the apoptotic signal pathways. |
• | TRAIL and TRAIL receptor agonists constitute potential therapy for HCC. |
• | TRAIL may stand a chance for therapy for virus hepatitis in the future. |
• | TRAIL deters autoimmune inflammation and ameliorates liver fibrosis and cirrhosis. |
Abstract |
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL has recently been suggested as a potential therapeutic target in hepatocellular carcinoma (HCC) because it promotes apoptosis in cancer cells. Furthermore, studies on the role of TRAIL in liver injury have reported that TRAIL plays an essential role in viral hepatitis, fatty liver diseases, etc. However, several contradictory and confounding effects of TRAIL in these liver diseases have not been fully elucidated or placed into perspective. Hence, this review summarizes recent progress in studies on TRAIL, including its role in apoptotic signaling, potential therapeutic applications of TRAIL in HCC, hepatitis virus infection, and liver fibrosis and cirrhosis.
Le texte complet de cet article est disponible en PDF.Keywords : Apoptosis, Hepatocellular carcinoma, TRAIL, Liver disease
Plan
Vol 110
P. 641-645 - février 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?